Singapore’s Mirxes to list in Hong Kong after securing $50M in Series D funding

Mirxes Holding Company Limited, a Singapore-headquartered biotech firm, announced Tuesday that it has filed listing application with The Stock Exchange of Hong Kong Limited after securing $50 million Series D funding.

MiRXES secures $77M Series C funding to accelerate multi-cancer early detection pipeline

Led by CR-CP Life Science Fund, this new capital will support MiRXES’s growth as a global leader in cancer early detection tests and preventive healthcare.